Form 4: Neurocrine Biosciences CFO Matt Abernethy Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Neurocrine Biosciences' CFO, Matt Abernethy, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On August 13, 2024, Matt Abernethy, the Chief Financial Officer of Neurocrine Biosciences Inc., exercised options to acquire 14,100 shares of common stock at a price of $73.60.
- Simultaneously, Abernethy sold 14,100 shares of common stock at a weighted average price of $150.3792, with individual sales ranging from $150.00 to $151.35.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on February 13, 2024.
- Following these transactions, Abernethy directly owns 31,528 shares of Neurocrine Biosciences Inc.
- Abernethy also holds options for 0 shares of Neurocrine Biosciences Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock transactions are common and closely monitored, especially in the biotech industry. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
- Sales under 10b5-1 plans are a common mechanism for executives to diversify their holdings while avoiding accusations of insider trading, similar to practices at companies like Amgen and Gilead Sciences.
- The reported weighted average sales price of $150.3792 is within a typical range for stock sales by executives at comparable biotech firms.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on inside information.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 2017-12-01 | Option granted |
| 2018-12-01 | First vesting anniversary of option grant (25%) |
| 2019-01-01 | Remaining 75% of option vested in 36 equal monthly installments |
| 2024-02-13 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-08-13 | Date of transaction: Exercise of stock options and sale of shares |
| 2027-12-01 | Expiration date of Non-Qualified Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.